WHO ICTRP trial
A Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease
CTRI/2021/04/032702 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2021/04/032702 |
|---|---|
| Public title | A Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease |
| Scientific title | A Phase 3, Randomized, Double-blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease - MITIGATE |
| Primary sponsor | Viela Bio acquired by Horizon Therapeutics |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States of America;Argentina |
| Conditions | Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified |
| Interventions | Intervention1: Inebilizumab: Inebilizumab administered as an IV infusion. Inebilizumab is a monoclonal antibody that depletes B cells. Control Intervention1: Placebo: Placebo administered as an IV infusion. |
| Registration date | Sep 4, 2021 |
| Target size | 200 |
| Secondary IDs | 2020-000417-33;NCT04540497 ;VIB0551.P3.S2 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: